May 12th 2025
May 9th 2025
A coalition of over 100 US companies is supporting the federal initiative to end the HIV epidemic by 2030, but legal and funding threats now jeopardize this progress and the significant health and economic benefits it promises.
May 1st 2025
As the cohort of people living with HIV in the US ages, HIV care programs must rapidly adapt to the changing needs of older adults with HIV.
April 22nd 2025
April 15th 2025
In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.
Cabotegravir Plus Rilpivirine Well-Received by HIV Care Staff, Patients at 12 Months
New findings from CUSTOMIZE suggest the once-monthly injection therapy was feasibly implemented and generally favored to once-daily tablets.
Read More
Study: Homeless Persons with HIV Prefer Flexible Care Models, No Telehealth
Perspective gained from persons treated a real-world clinic may help better inform strategies to treat an HIV population that often struggles with viral suppression and consistent care.
Watch
COVID-19 Severe Risks Not Significant in People with HIV
A new study from IAS 2021 suggests persons with HIV hospitalized for COVID-19 do not face worse mortality nor major cardiovascular event risk.
FDA Approves Expanded Indication for Secnidazole for Trichomoniasis
The therapy, developed by Lupin Pharmaceuticals, now includes the treatment of trichomoniasis in adults patients and their partners.
Long-Acting Antiretroviral Therapies for HIV Treatment and Prevention
More treatment options and modalities are now available for patients.
Public Health Watch: Latest STI Numbers for US a “Call to Action”
CDC report highlights disparities among “racial, ethnic, gender, and sexual” minorities.
NAFLD Is Increasingly Affecting Patients With HIV
The prevalence of this disease in this patient population is much higher than in the general public.
Tenofovir Disoproxil Fumarate Linked to Less HIV Metabolic, BMI Risk than Tenofovir Alafenamide
A new cohort assessment evidences a disparity in weight-related outcomes with the ART regimens at 18 months.
Tuberculosis Testing in New HIV Patients Does Not Effect ART Regimen
A comparative study of same-day and seven-day TB test results show there is little difference in HIV treatment adherence or outcomes at 48 weeks.
HTI Vaccine Regimen Shows Immunogenicity in HIV Patients
Phase 1/2 trial results showed the immunomodulary vaccine regimen could induce significant T-cell response in patients with HIV.
HIV CRISPR Screen Provides Novel Dependency Factors
New research from the Emerman Lab at Fred Hutchinson shows potential for advancing HIV-1 life cycle understanding.
Inflammation Could Help Predict HIV Women Cardiovascular Risks
Presented at CROI, investigators have identified sex-modified inflammatory predictors of cardiovascular and VTE risks among patients with HIV.
The Future Fight of HIV
A talk on optimistic, but pragmatic hopes for HIV cure and vaccine research, led by federal-level experts.
Chris Beyrer, MD, MPH: Evolving HIV Movements
Attention to the endemic virus has lessened over years, and screening and prevention access remains limited among the most at-risk groups.
The Current State of HIV in the United States
A John Hopkins expert and major study leader details the evolving epidemiology of the virus.
FDA Approves First Long-Acting Injectable Drug for HIV
The cabotegravir and rilpivirine formulation was approved on the basis of 2 trials assessing its viral suppression capability in 1100-plus adults with HIV.
First Case of Neisseria Gonorrhoeae Mosaic PenA60 Allele Identified in United States
The U.S. sentinel surveillance program is a project which monitors for antibiotic-resistant gonorrhea.
Can FDA-Approved MS Drug Block HIV Infection?
In testing, fingolimod blocked cell-free and cell-to-cell transmission of HIV, reducing latent virus.
Interferon-Stimulated Gene Inhibits HCV Replication
Study explores the antiviral mechanisms of C19orf66, an interferon-induced inhibitor.
Adolescent HIV Prevention: Overcoming the PrEP "Purview Paradox"
Conversations about PrEP with a clinician are the least common among adolescents with the greatest risk for HIV.
COVID-19 in People Living With HIV
A hospital case series of patients with both COVID-19 and HIV describes recovery, but highlights the need to refine treatment.
Acute Hepatitis C Infections Triple from 2009-2018
The CDC is calling for all adults to get tested for hepatitis C after the annual rate of infections tripled between 2009 and 2019.
CDC Issues New HCV Screening Recommendations
The 2 new recommendations are for HCV screening at least once for all adults aged 18 years or older and HCV screening for women during each pregnancy.
Examining HIV Training Pathways in Residency
HIV training pathways in residency have added 90 HIV physicians to the workforce since 2006.
Ending the HIV Epidemic Initiative: A Snapshot From the Trenches, 1 Year Later
Funded jurisdictions scramble to meet daunting deadlines yet maintain optimism that the new federal initiative can end flat funding and catalyze progress.
Prodrug Fostemsavir Lowers Viral HIV Levels
When drug resistance means ART options are exhausted, HIV patients need newer choices. A new study shows that novel prodrug fostemsavir is an effective alternative.
Living and Aging With HIV: Recognition and Management of Common Prescribing Pitfalls
With advancements in antiretroviral therapy, people with HIV are now living longer and developing age-related chronic conditions.
State Medicaid Reimbursement for Routine HIV Screening
Safety Profiles of FDA-Approved PrEP Agents
PrEP Therapy for High-Risk HIV Candidates
